Labcorp study suggests COVID-19 antibodies remain at least 10 months after infection
Study of More Than 39,000 People Also Investigated Impact of Age, Sex on Antibody Endurance
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210524005818/en/
The study, published
“Our observational analysis provides an encouraging timeline for antibody development and sustainability among the
Alfego and a team of
By employing various techniques,
Notable findings include:
- While sample sizes varied each day after a positive COVID-19 test, the antibody positivity rate to the SARS-CoV-2 spike protein remained mostly stable for the
U.S. population through 300 days after the initial test. - The positivity rate of antibodies to the nucleocapsid protein—a coronavirus component that is more active during early infection—declined more rapidly than the rate of spike antibodies but remained above 60% through 10 months of testing.
- Individuals under the age of 65 showed a more sustained rate of positive antibody results, meaning those 65 and older may have increased difficulty maintaining antibodies for a prolonged period of time.
- There was no statistically significant difference in spike antibody positivity rates between males and females over time.
“This is good news for naturally infected individuals, and potentially for those who have been vaccinated,” said
The research, another example of Labcorp’s significant involvement in the country’s COVID-19 response, can be accessed here.
About
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements, including but not limited to statements with respect to our responses to and the expected future impacts of the COVID-19 pandemic, scientific collaborations, customer contracts and relationships, the anticipated benefits of such collaboration and relationships, and the expected impact that the various collaborations and customer relationships may have on the Company’s financial results. Each of the forward-looking statements is subject to change based on various important factors, many of which are beyond the Company’s control, including without limitation, whether our responses to the COVID-19 pandemic will prove effective, the impact of the COVID-19 pandemic on our business and financial condition as well as on general economic, business, and market conditions, the Company’s ability to establish and maintain strategic partnerships and other scientific collaborations, competitive actions in the marketplace, changes in government regulations, including healthcare reform, customer purchasing decisions, including changes in payer regulations or policies, adverse actions of governmental and other third-party payers, patient safety issues, changes in testing guidelines or recommendations, and federal, state, and local governmental responses to the COVID-19 pandemic. These factors, in some cases, have affected and in the future (together with other factors) could affect the Company’s ability to implement the company’s business strategy and actual results could differ materially from those suggested by these forward-looking statements. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements. The Company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Further information on potential factors, risks and uncertainties that could affect operating and financial results is included in the Company’s most recent Annual Report on Form 10-K and subsequent Forms 10-Q, including in each case under the heading RISK FACTORS, and in the Company’s other filings with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20210524005818/en/
Labcorp Contacts:
Media:
[email protected]
Investors:
[email protected]
Source: